Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Weight loss pacemaker company Enteromedics gearing up for commercial launch
EnteroMedics lost money again in 2014 but the Minnesota developer of a neurostimulation implant to treat obesity expects to address the red ink in the coming months, as it gears up for a commercial launch of its signature device.
“Execution of our commercial strategy is well underway following the FDA approval that was received earlier this year,” Greg Lea, the company’s chief financial officer and chief operating officer, said in prepared remarks. “We believe that our current resources will permit us to start to build the necessary infrastructure, invest in inventory, fund product improvements and implement process changes to support our commercial strategy.” Read more
2. Epilepsy: Medtronic touts 5 year results on SANTE trial
Medtronic’s deep brain stimulation therapy for treatment-resistant epilepsy helped patients achieve major and prolonged periods with fewer seizures after 5 years, according final, detailed results from a pivotal clinical trial.
All the long-term data from the medical device giant’s SANTE trial is detailed online in the journal Neurology, which will also publish the findings in its March 2015 print issue. Read more
1. Report: Cardinal Health top suitor for J&J’s Cordis unit
Healthcare giant Johnson & Johnson may have found a buyor for its Cordis business, according to Bloomberg News.
Cardinal Health has emerged as the leading suitor to buy Cordis, which makes stents, catheters and other vascular devices,according to the news service. Spokesman for J&J and Cardinal declined to comment on the rumor to Bloomberg. Anonymous sources told the Wall Street Journal in August that Cordis could command a $1.5 billion to $2 billion price tag. Read more
